Originally published Aug. 24.

Arrayit said this week that it has submitted an application for premarket approval with the US Food and Drug Administration for its OvaDx Pre-Symptomatic Ovarian Cancer Screening Test.

"While the standard for a PMA is higher than for a 510(k), the company believes that a PMA OvaDx submission can achieve a Class III PMA approval, the most stringent approval level granted by the FDA for in vitro diagnostic devices," the company said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.